Kiffik Biomedical

About Kiffik Biomedical

Kiffik Biomedical is a pioneering company in the health technology sector, specializing in noninvasive diagnostic devices. The company has developed a groundbreaking device that continuously extracts and analyzes interstitial fluid, identifying up to 10,000 unique compounds and biomarkers. This technology is designed to accommodate all skin types and is universally accessible via smart device connection, making it suitable for a wide range of demographics. Kiffik's device offers a significant advantage by being noninvasive, eliminating the need for needles or penetrating probes, and avoiding immune system responses and inflammation. This allows for continuous health monitoring without the need for a doctor's office or laboratory visits.

Kiffik Biomedical serves a diverse clientele, including individuals monitoring their health, athletes seeking to optimize fitness and endurance, and veterinarians assessing the health of animals. The company operates in the health technology market, focusing on both human and animal health. Its business model revolves around the sale of its diagnostic devices and potentially subscription-based services for continuous health monitoring. Revenue is generated through direct sales, partnerships, and possibly future licensing agreements.

Founded in the first quarter of 2021, Kiffik has made significant strides, including acquiring extraction technology, signing an agreement with the University of Birmingham's PHTA, and raising $12 million in Series A funding. The company is currently in the process of obtaining FDA approval for its device.